Skip to main content
Erschienen in: Tumor Biology 6/2014

01.06.2014 | Research Article

Rsf-1 overexpression in human prostate cancer, implication as a prognostic marker

verfasst von: Hui Li, Yi Zhang, Yue Zhang, Xue Bai, Yang Peng, Ping He

Erschienen in: Tumor Biology | Ausgabe 6/2014

Einloggen, um Zugang zu erhalten

Abstract

Rsf-1 (HBXAP) was recently reported to be overexpressed in various cancers and associated with the malignant behavior of cancer cells. However, the expression of Rsf-1 and its clinical significance in human prostate cancer have not been reported. In the present study, we analyzed the expression pattern of Rsf-1 in human prostate cancer tissues and found that Rsf-1 was overexpressed in 45 % of prostate cancer specimens. There was a significant association between Rsf-1 overexpression and tumor stage (p = 0.0039) and preoperative PSA level (p = 0.015). Furthermore, Rsf-1 overexpression correlated with poor biomedical recurrence-free survival in prostate cancer patients (p < 0.001). Rsf-1 overexpression could serve as an independent predictor for poor recurrence-free survival (p = 0.012). In addition, small interfering RNA (siRNA) knockdown in DU145 cells with high endogenous Rsf-1 expression decrease cell proliferation, colony formation, and invasion. In conclusion, Rsf-1 is overexpressed in human prostate cancers and serves as a novel prognostic marker. Rsf-1 contributes to prostate cancer cell growth and invasion, which makes it a candidate therapeutic target.
Literatur
1.
2.
Zurück zum Zitat Yaqinuddin A, Qureshi SA, Pervez S, Bashir MU, Nazir R, Abbas F. Frequent DNA hypermethylation at the RASSF1A and APC gene loci in prostate cancer patients of Pakistani origin. ISRN Urol. 2013;2013:627249.PubMedCentralPubMed Yaqinuddin A, Qureshi SA, Pervez S, Bashir MU, Nazir R, Abbas F. Frequent DNA hypermethylation at the RASSF1A and APC gene loci in prostate cancer patients of Pakistani origin. ISRN Urol. 2013;2013:627249.PubMedCentralPubMed
4.
Zurück zum Zitat Syeed N, Syed Sameer A, Hamid A, Shah ZA, Afroze D, Rasool R, et al. Promoter methylation profile of GSTP1 and RASSF1A in benign hyperplasia and metastatic prostate cancer patients in a Kashmiri population. Mol Med Rep. 2010;3(5):883–7.PubMed Syeed N, Syed Sameer A, Hamid A, Shah ZA, Afroze D, Rasool R, et al. Promoter methylation profile of GSTP1 and RASSF1A in benign hyperplasia and metastatic prostate cancer patients in a Kashmiri population. Mol Med Rep. 2010;3(5):883–7.PubMed
5.
Zurück zum Zitat Davidson B, Trope CG, Wang TL, Shih Ie M. Expression of the chromatin remodeling factor Rsf-1 is upregulated in ovarian carcinoma effusions and predicts poor survival. Gynecol Oncol. 2006;103(3):814–9.CrossRefPubMed Davidson B, Trope CG, Wang TL, Shih Ie M. Expression of the chromatin remodeling factor Rsf-1 is upregulated in ovarian carcinoma effusions and predicts poor survival. Gynecol Oncol. 2006;103(3):814–9.CrossRefPubMed
6.
Zurück zum Zitat Shih Ie M, Sheu JJ, Santillan A, Nakayama K, Yen MJ, Bristow RE, et al. Amplification of a chromatin remodeling gene, Rsf-1/HBXAP, in ovarian carcinoma. Proc Natl Acad Sci U S A. 2005;102(39):14004–9.CrossRefPubMed Shih Ie M, Sheu JJ, Santillan A, Nakayama K, Yen MJ, Bristow RE, et al. Amplification of a chromatin remodeling gene, Rsf-1/HBXAP, in ovarian carcinoma. Proc Natl Acad Sci U S A. 2005;102(39):14004–9.CrossRefPubMed
7.
Zurück zum Zitat Huang X, Gollin SM, Raja S, Godfrey TE. High-resolution mapping of the 11q13 amplicon and identification of a gene, TAOS1, that is amplified and overexpressed in oral cancer cells. Proc Natl Acad Sci U S A. 2002;99(17):11369–74.PubMedCentralCrossRefPubMed Huang X, Gollin SM, Raja S, Godfrey TE. High-resolution mapping of the 11q13 amplicon and identification of a gene, TAOS1, that is amplified and overexpressed in oral cancer cells. Proc Natl Acad Sci U S A. 2002;99(17):11369–74.PubMedCentralCrossRefPubMed
8.
Zurück zum Zitat Li Q, Dong Q, Wang E. Rsf-1 is overexpressed in non-small cell lung cancers and regulates cyclinD1 expression and ERK activity. Biochem Biophys Res Commun. 2012;420(1):6–10.CrossRefPubMed Li Q, Dong Q, Wang E. Rsf-1 is overexpressed in non-small cell lung cancers and regulates cyclinD1 expression and ERK activity. Biochem Biophys Res Commun. 2012;420(1):6–10.CrossRefPubMed
9.
Zurück zum Zitat Liu S, Dong Q, Wang E. Rsf-1 overexpression correlates with poor prognosis and cell proliferation in colon cancer. Tumour Biol. 2012;33(5):1485–91.CrossRefPubMed Liu S, Dong Q, Wang E. Rsf-1 overexpression correlates with poor prognosis and cell proliferation in colon cancer. Tumour Biol. 2012;33(5):1485–91.CrossRefPubMed
10.
Zurück zum Zitat Sheu JJ, Choi JH, Guan B, Tsai FJ, Hua CH, Lai MT, et al. Rsf-1, a chromatin remodelling protein, interacts with cyclin E1 and promotes tumour development. J Pathol. 2013;229(4):559–68.PubMedCentralCrossRefPubMed Sheu JJ, Choi JH, Guan B, Tsai FJ, Hua CH, Lai MT, et al. Rsf-1, a chromatin remodelling protein, interacts with cyclin E1 and promotes tumour development. J Pathol. 2013;229(4):559–68.PubMedCentralCrossRefPubMed
11.
Zurück zum Zitat Davidson B, Wang TL, Shih Ie M, Berner A. Expression of the chromatin remodeling factor Rsf-1 is down-regulated in breast carcinoma effusions. Hum Pathol. 2008;39(4):616–22.PubMedCentralCrossRefPubMed Davidson B, Wang TL, Shih Ie M, Berner A. Expression of the chromatin remodeling factor Rsf-1 is down-regulated in breast carcinoma effusions. Hum Pathol. 2008;39(4):616–22.PubMedCentralCrossRefPubMed
12.
Zurück zum Zitat Wahafu W, He ZS, Zhang XY, Zhang CJ, Yao K, Hao H, et al. The nucleosome binding protein NSBP1 is highly expressed in human bladder cancer and promotes the proliferation and invasion of bladder cancer cells. Tumour Biol. 2011;32(5):931–9.CrossRefPubMed Wahafu W, He ZS, Zhang XY, Zhang CJ, Yao K, Hao H, et al. The nucleosome binding protein NSBP1 is highly expressed in human bladder cancer and promotes the proliferation and invasion of bladder cancer cells. Tumour Biol. 2011;32(5):931–9.CrossRefPubMed
13.
14.
Zurück zum Zitat Klochendler-Yeivin A, Muchardt C, Yaniv M. SWI/SNF chromatin remodeling and cancer. Curr Opin Genet Dev. 2002;12(1):73–9.CrossRefPubMed Klochendler-Yeivin A, Muchardt C, Yaniv M. SWI/SNF chromatin remodeling and cancer. Curr Opin Genet Dev. 2002;12(1):73–9.CrossRefPubMed
15.
Zurück zum Zitat Wolffe AP. Chromatin remodeling: why it is important in cancer. Oncogene. 2001;20(24):2988–90.CrossRefPubMed Wolffe AP. Chromatin remodeling: why it is important in cancer. Oncogene. 2001;20(24):2988–90.CrossRefPubMed
16.
Zurück zum Zitat Hennessy BT, Nanjundan M, Cheng KW, Nolden L, Mills GB. Identification of remodeling and spacing factor 1 (rsf-1, HBXAP) at chromosome 11q13 as a putative oncogene in ovarian cancer. Eur J Hum Genet. 2006;14(4):381–3.CrossRefPubMed Hennessy BT, Nanjundan M, Cheng KW, Nolden L, Mills GB. Identification of remodeling and spacing factor 1 (rsf-1, HBXAP) at chromosome 11q13 as a putative oncogene in ovarian cancer. Eur J Hum Genet. 2006;14(4):381–3.CrossRefPubMed
17.
Zurück zum Zitat Brown LA, Irving J, Parker R, Kim H, Press JZ, Longacre TA, et al. Amplification of EMSY, a novel oncogene on 11q13, in high grade ovarian surface epithelial carcinomas. Gynecol Oncol. 2006;100(2):264–70.CrossRefPubMed Brown LA, Irving J, Parker R, Kim H, Press JZ, Longacre TA, et al. Amplification of EMSY, a novel oncogene on 11q13, in high grade ovarian surface epithelial carcinomas. Gynecol Oncol. 2006;100(2):264–70.CrossRefPubMed
18.
Zurück zum Zitat Bostner J, Ahnstrom Waltersson M, Fornander T, Skoog L, Nordenskjold B, Stal O. Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer. Oncogene. 2007;26(49):6997–7005.CrossRefPubMed Bostner J, Ahnstrom Waltersson M, Fornander T, Skoog L, Nordenskjold B, Stal O. Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer. Oncogene. 2007;26(49):6997–7005.CrossRefPubMed
19.
Zurück zum Zitat Cheng CK, Chow LW, Loo WT, Chan TK, Chan V. The cell cycle checkpoint gene Rad9 is a novel oncogene activated by 11q13 amplification and DNA methylation in breast cancer. Cancer Res. 2005;65(19):8646–54.CrossRefPubMed Cheng CK, Chow LW, Loo WT, Chan TK, Chan V. The cell cycle checkpoint gene Rad9 is a novel oncogene activated by 11q13 amplification and DNA methylation in breast cancer. Cancer Res. 2005;65(19):8646–54.CrossRefPubMed
20.
Zurück zum Zitat Rosen A, Sevelda P, Klein M, Dobianer K, Hruza C, Czerwenka K, et al. First experience with FGF-3 (INT-2) amplification in women with epithelial ovarian cancer. Br J Cancer. 1993;67(5):1122–5.PubMedCentralCrossRefPubMed Rosen A, Sevelda P, Klein M, Dobianer K, Hruza C, Czerwenka K, et al. First experience with FGF-3 (INT-2) amplification in women with epithelial ovarian cancer. Br J Cancer. 1993;67(5):1122–5.PubMedCentralCrossRefPubMed
21.
Zurück zum Zitat Seki A, Yoshinouchi M, Seki N, Kodama J, Miyagi Y, Kudo T. Detection of c-erbB-2 and FGF-3 (INT-2) gene amplification in epithelial ovarian cancer. Int J Oncol. 2000;17(1):103–6.PubMed Seki A, Yoshinouchi M, Seki N, Kodama J, Miyagi Y, Kudo T. Detection of c-erbB-2 and FGF-3 (INT-2) gene amplification in epithelial ovarian cancer. Int J Oncol. 2000;17(1):103–6.PubMed
22.
Zurück zum Zitat Fang FM, Li CF, Huang HY, Lai MT, Chen CM, Chiu IW, et al. Overexpression of a chromatin remodeling factor, RSF-1/HBXAP, correlates with aggressive oral squamous cell carcinoma. Am J Pathol. 2011;178(5):2407–15.PubMedCentralCrossRefPubMed Fang FM, Li CF, Huang HY, Lai MT, Chen CM, Chiu IW, et al. Overexpression of a chromatin remodeling factor, RSF-1/HBXAP, correlates with aggressive oral squamous cell carcinoma. Am J Pathol. 2011;178(5):2407–15.PubMedCentralCrossRefPubMed
23.
Zurück zum Zitat Kawamoto K, Okino ST, Place RF, Urakami S, Hirata H, Kikuno N, et al. Epigenetic modifications of RASSF1A gene through chromatin remodeling in prostate cancer. Clin Cancer Res. 2007;13(9):2541–8.CrossRefPubMed Kawamoto K, Okino ST, Place RF, Urakami S, Hirata H, Kikuno N, et al. Epigenetic modifications of RASSF1A gene through chromatin remodeling in prostate cancer. Clin Cancer Res. 2007;13(9):2541–8.CrossRefPubMed
24.
Zurück zum Zitat Slupianek A, Yerrum S, Safadi FF, Monroy MA. The chromatin remodeling factor SRCAP modulates expression of prostate specific antigen and cellular proliferation in prostate cancer cells. J Cell Physiol. 2010;224(2):369–75.CrossRefPubMed Slupianek A, Yerrum S, Safadi FF, Monroy MA. The chromatin remodeling factor SRCAP modulates expression of prostate specific antigen and cellular proliferation in prostate cancer cells. J Cell Physiol. 2010;224(2):369–75.CrossRefPubMed
25.
Zurück zum Zitat Sheu JJ, Guan B, Choi JH, Lin A, Lee CH, Hsiao YT, et al. Rsf-1, a chromatin remodeling protein, induces DNA damage and promotes genomic instability. J Biol Chem. 2010;285(49):38260–9.PubMedCentralCrossRefPubMed Sheu JJ, Guan B, Choi JH, Lin A, Lee CH, Hsiao YT, et al. Rsf-1, a chromatin remodeling protein, induces DNA damage and promotes genomic instability. J Biol Chem. 2010;285(49):38260–9.PubMedCentralCrossRefPubMed
26.
Zurück zum Zitat Choi JH, Sheu JJ, Guan B, Jinawath N, Markowski P, Wang TL, et al. Functional analysis of 11q13.5 amplicon identifies Rsf-1 (HBXAP) as a gene involved in paclitaxel resistance in ovarian cancer. Cancer Res. 2009;69(4):1407–15.PubMedCentralCrossRefPubMed Choi JH, Sheu JJ, Guan B, Jinawath N, Markowski P, Wang TL, et al. Functional analysis of 11q13.5 amplicon identifies Rsf-1 (HBXAP) as a gene involved in paclitaxel resistance in ovarian cancer. Cancer Res. 2009;69(4):1407–15.PubMedCentralCrossRefPubMed
27.
Zurück zum Zitat Sheu JJ, Choi JH, Yildiz I, Tsai FJ, Shaul Y, Wang TL, et al. The roles of human sucrose nonfermenting protein 2 homologue in the tumor-promoting functions of Rsf-1. Cancer Res. 2008;68(11):4050–7.PubMedCentralCrossRefPubMed Sheu JJ, Choi JH, Yildiz I, Tsai FJ, Shaul Y, Wang TL, et al. The roles of human sucrose nonfermenting protein 2 homologue in the tumor-promoting functions of Rsf-1. Cancer Res. 2008;68(11):4050–7.PubMedCentralCrossRefPubMed
28.
Zurück zum Zitat Mazumder S, DuPree EL, Almasan A. A dual role of cyclin E in cell proliferation and apoptosis may provide a target for cancer therapy. Curr Cancer Drug Targets. 2004;4(1):65–75.PubMedCentralCrossRefPubMed Mazumder S, DuPree EL, Almasan A. A dual role of cyclin E in cell proliferation and apoptosis may provide a target for cancer therapy. Curr Cancer Drug Targets. 2004;4(1):65–75.PubMedCentralCrossRefPubMed
29.
Zurück zum Zitat Okuda M, Horn HF, Tarapore P, Tokuyama Y, Smulian AG, Chan PK, et al. Nucleophosmin/B23 is a target of CDK2/cyclin E in centrosome duplication. Cell. 2000;103(1):127–40.CrossRefPubMed Okuda M, Horn HF, Tarapore P, Tokuyama Y, Smulian AG, Chan PK, et al. Nucleophosmin/B23 is a target of CDK2/cyclin E in centrosome duplication. Cell. 2000;103(1):127–40.CrossRefPubMed
Metadaten
Titel
Rsf-1 overexpression in human prostate cancer, implication as a prognostic marker
verfasst von
Hui Li
Yi Zhang
Yue Zhang
Xue Bai
Yang Peng
Ping He
Publikationsdatum
01.06.2014
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 6/2014
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-1766-7

Weitere Artikel der Ausgabe 6/2014

Tumor Biology 6/2014 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.